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Diabetogenic effect of statins: 
a comprehensive review on the 
clinical relevance, underlying 
pathomechanisms and rationale  
for tailored statin therapy
ABSTRACT
Statins are potent hypolipidemic drugs effectively reducing low-density lipoprotein (LDL) cholesterol serum 
concentration, but also exerting a wide range of pleiotropic effects. In numerous clinical trials statins were 
proven to substantially decrease cardiovascular morbidity and mortality both in primary and secondary 
prevention. However, a growing body of evidence suggests that statins, although safe and generally 
well-tolerated, are associated with an increased occurrence of new-onset diabetes mellitus (DM). The 
aim of this review is to explore the relationship between statin therapy and new-onset DM, including its 
clinical relevance and underlying pathomechanisms, and to discuss the concept of tailored statin therapy. 
According to our recently published comprehensive network meta-analysis including 113,394 patients, 
the high-dose statin regimens were connected with an elevated risk of new-onset DM as compared with 
moderate-dose statin regimens and a gradient for the risk of new-onset DM across different types and 
doses of statins was demonstrated. There are multiple possible mechanisms explaining the diabeto-
genic effect of statins (e.g., decreased insulin secretion, induction of b-cell apoptosis, increased insulin 
resistance or compromised glucose transport into the cells). Statins are among the most widely used 
drugs worldwide and physicians should be aware of the fact that there is a risk of new-onset DM across 
different types and doses of statins. Selection of adequate statin that suits patient’s needs remains the 
challenge of hypolipidemic therapy. The identification of individuals who would benefit more from smaller 
doses and/or use of less diabetogenic compounds could help to optimize the treatment and reduce 
the number of patients developing DM. The non-pharmacological approach such as adequate physical 
activity, weight reduction and low fat diet should not be neglected either. These actions create a chance 
to decrease baseline LDL-cholesterol concentration and reduce the number of both cardiovascular and 
DM risk factors. All in all, statins with their exceptional cardiovascular benefits will undoubtedly defend 
their position of a cornerstone of cardiovascular prevention because profits derived from statin therapy far 
exceed the potential harms connected with statin-induced impairments of glucose metabolism.
Key words: diabetes, diabetogenicity, statins, hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors, adverse effects, personalized statin therapy
Folia Medica Copernicana 2015; 3 (4): 145–153
Corresponding author: 
Małgorzata Ostrowska, MD, PhD
Department of Principles of Clinical 
Medicine
Collegium Medicum, Nicolaus  
Copernicus University
9 Skłodowskiej-Curie Street
85–094 Bydgoszcz, Poland
Tel.: +48 52 585 40 23
Fax: +48 52 585 40 24
E-mail: ostrowska.go@gmail.com
Folia Medica Copernicana 2015; 
Volume 3, Number 4, 145–153  
10.5603/FMC.2015.0009
Copyright © 2015 Via Medica 
ISSN 2300–5432
Introduction
Statins are potent hypolipidemic drugs which selec-
tively and reversibly inhibit the enzyme 3-hydroxy-meth-
ylglutaryl coenzyme A (HMG-CoA) reductase. These 
agents suppress cholesterol synthesis in the liver and 
increase expression of low-density lipoprotein (LDL) re-
ceptors in hepatocytes leading to enhanced LDL-choles-
terol uptake. Both actions finally result in a reduced con-
centration of LDL-cholesterol in the bloodstream [1–4]. 
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Apart from the influence on LDL-cholesterol concen-
tration, statins also exert a wide range of pleiotropic 
effects, including anti-inflammatory and anti-oxidative 
properties, stabilization of atherosclerotic plaques, 
decreased blood thrombogenicity, and improvement 
of endothelial function [5–8]. Most importantly, in nu-
merous clinical trials statins were proven to substantially 
decrease cardiovascular morbidity and mortality both 
in primary and secondary prevention [9–25]. Based on 
the observation that even a modest impact of statins 
on LDL-cholesterol concentration and atherosclerotic 
plaque burden is associated with the substantially re-
duced rate of cardiovascular events, the above listed 
pleiotropic effects are suggested to be at least partially 
responsible for clinical benefits of statin therapy.
Since the first group representative, lovastatin, was 
introduced to the market in 1987, statins have become 
one of the most frequently prescribed drugs worldwide. 
A growing body of evidence suggests that statins, 
although safe and generally well-tolerated, are asso-
ciated with several adverse events, with the increased 
occurrence of new-onset diabetes mellitus (DM) being 
the most widely discussed in recent years [26–29]. 
These findings have even forced the US Food and Drug 
Administration to add information to statin labels about 
the increased risk of raised blood glucose concentration 
and development of type 2 DM [30].
Our recently published meta-analysis constitutes the 
largest and the most comprehensive so far conducted 
evaluation of the risk of new-onset DM associated with 
different types and doses of statins [31]. we believe that 
the findings of this meta-analysis, if properly applied in 
clinical practice, could help personalize statin therapy 
and confine the adverse diabetogenic effect of statins 
in specific patient subsets. 
The present review aims to explore the relationship 
between statin therapy and new-onset DM, including 
its clinical relevance and underlying pathomechanisms, 
and to discuss the concept of tailored statin therapy.
Search strategy
A search covering the period from November 
1994 through October 2015 was conducted by two 
independent investigators using MEDLINE, CENTRAL 
and Google Scholar databases. Proceedings from the 
Scientific Sessions of the American College of Cardiol-
ogy [http://www.acc.org], American Heart Association 
[http://www.heart.org], the European Society of Car-
diology [http://www.escardio.org], Transcatheter Car-
diovascular Therapeutics [http://www.tctmd.com] and 
EuroPCR [http://www.europcr.com] were also consid-
ered. The following keywords were applied: “diabetes”, 
“diabetogenicity”, “glucose”, “statin”, “hydroxy-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitors”, 
“adverse effect”. References of the retrieved studies 
were searched manually for additional studies and 
reviews. No language restrictions were applied. 
Overview of studies linking statin 
therapy with new-onset DM
The first report of possible connection between sta-
tin therapy and the development of new-onset DM was 
published in 2001 by the authors of a post hoc analysis 
of the wOSCOPS (West of Scotland Coronary Prevention 
Study) trial, a randomized placebo-controlled study 
including 5974 men with hypercholesterolemia and 
no history of myocardial infarction [11]. Unexpectedly, 
the study indicated a 30% reduction in the incidence 
of DM among pravastatin- vs. placebo-treated patients 
(hazard ratio [HR] 0.70; 95% confidence interval [CI] 
CI 0.50–0.99). However, it needs to be acknowledged 
that the authors used non-standardized criteria for the 
DM diagnosis.
This protective effect of statins on new-onset DM 
occurrence was not confirmed in subsequent clinical 
studies. On the contrary, the results of the JUPITER 
(Justification for the Use of Statins in Primary Preven-
tion: an Intervention Trial Evaluating Rosuvastatin) trial 
indicated quite the opposite [12]. Despite the fact that in 
17,802 apparently healthy men 50 years of age or older, 
and women 60 years of age or older, with LDL-cholester-
ol concentration of less than 130 mg/dL and C-reactive 
protein concentrations of 2.0 mg/L or higher, rosuvasta-
tin 20 mg q.s., as compared with placebo, was proven 
to significantly reduce the primary study endpoint, 
a composite of myocardial infarction, stroke, unstable 
angina, necessity of arterial revascularization procedure 
and death from cardiovascular causes, it simultaneously 
raised the rate of newly diagnosed DM and increased 
the median value of glycated hemoglobin.
Numerous other randomized clinical trials, whose 
both design and major findings are summarized in Table 1, 
also suggested excess of new-onset DM in statin- 
v. placebo-treated patients.
Furthermore, Rajpathak et al. in a meta-analysis of 
five randomized statin trials reported an overall risk ratio 
(RR) of 1.13 with a 95% CI ranging from 1.03 to 1.23 for 
new-onset DM in statin-treated patients as compared 
with the placebo/no treatment group [26]. However, 
when the data from the wOSCOPS trial was included in 
the meta-analysis, the RR value decreased to 1.06 and 
was no longer statistically significant (95% CI 0.93–1.25).
Another substantial argument supporting the diabe-
togenic effect of statins was delivered by Sattar and col-
leagues, who performed a meta-analysis of thirteen ran-
domized statin studies including 91,140 participants [28]. 
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During a mean follow-up of 4 years, 4278 patients de-
veloped DM, of whom 2226 and 2052 were in the statin 
and control groups, respectively. In this meta-analysis, 
statin therapy was associated with 9% higher risk of 
developing new-onset DM as compared with the con-
trol arm (OR 1.09; 95% CI 1.02–1.17). In other words, 
treatment of 255 patients with statins for period of 
4 years resulted in one additional case of DM. Interest-
ingly, meta-regression analysis showed that neither 
LDL-cholesterol concentration nor baseline body-mass 
index had any impact on the risk of DM development, 
whereas elderly age was associated with an increased 
occurrence of new-onset DM.
Likewise, the dosage of statins appears to be di-
rectly connected with their diabetogenicity. Preiss et al. 
investigated this hypothesis in a meta-analysis of five 
randomized statin trials including 32,752 participants 
without DM at baseline who were either assigned to 
high- or moderate-dose therapy [29]. Out of 2749 pa-
tients who developed DM during the follow-up, 1449 and 
1300 were treated with high- and moderate-dose 
statin therapy, respectively. The patients subjected to 
high-dose statin therapy, compared with participants 
on moderate-dose statin therapy, were more likely to 
develop DM (odds ratio [OR] 1.12; 95% CI 1.04–1.22), 
but at the same time suffered less major adverse car-
diovascular events (OR 0.84; 95% CI 0.75–0.94). The 
corresponding number-needed to treat (NNT) and 
number-needed to harm (NNH) values were 155 and 
498, respectively.
Recent network meta-analysis of 
impact of different types and doses of 
statins on new-onset DM
The outcomes of the aforementioned trials and 
analyses raised many concerns in the medical world 
and left us with unanswered questions of how to use 
statins in order to minimize the potential risk of generat-
ing new-onset DM and how to optimize their beneficial 
effects in cardiovascular prevention at the same time. 
These unsolved issues led us to conduct a compre-
hensive network meta-analysis, in which we compared 
the impact of different types and doses of statins on 
new-onset DM [31]. The data acquired from seventeen 
randomized controlled trials, covering 113,394 pa-
tients, were subjected to the investigation. Fourteen 
trials compared statin with placebo/no treatment and 
three studies compared high-dose (atorvastatin 80 mg 
q.s., lovastatin 20–40 mg q.s., pravastatin 40 mg q.s., 
rosuvastatin 20 mg q.s. or simvastatin 40 mg q.s.) 
with moderate-dose therapy (atorvastatin 10 mg q.s., 
pravastatin 10–20 mg q.s. or rosuvastatin 10 mg q.s.). 
Noteworthy, treatment with rosuvastatin 20 mg q.s. was 
found to increase the relative risk of DM incidence by 
25% compared with the placebo group, with a similar 
magnitude of increased risk observed in patients treat-
ed with simvastatin 40 mg q.s. Rosuvastatin was also 
associated with the highest risk of new-onset DM. On 
the other hand, pravastatin, both in high- and moder-
ate-doses, exposed meta-analysis participants at the 
lowest risk of DM as compared with placebo. Moreover, 
the risk for DM in subjects treated with pravastatin 40 mg 
q.s. did not differ very much from the risk observed in 
patients from the placebo group. Superior safety profile, 
in terms of the new-onset DM occurrence, of pravas-
tatin over rosuvastatin was also observed when these 
compounds were compared directly and a 16% relative 
risk reduction of the incidence of new-onset DM was 
reported in favor of pravastatin. Similarly, therapy with 
atorvastatin 80 mg q.s. resulted in approximately 8% 
relative risk reduction for new-onset DM compared with 
high-dose rosuvastatin. At moderate doses the risk of 
developing DM while using atorvastatin or rosuvastatin 
was comparable. In general, high-dose statin regimens 
were connected with elevated risk of new-onset DM as 
compared with moderate-dose statin regimens and 
a gradient for the risk of new-onset DM across different 
types and doses of statins was demonstrated.
Potential mechanisms underlying the 
diabetogenic effect of statins
There are multiple possible mechanisms which could 
serve as an explanation of the observed association be-
tween statin therapy and new-onset DM (Fig. 1). Statins 
Figure 1. Proposed mechanisms of statin diabetogenicity; 
ATP — adenosine triphosphate; GLUT — glucose transporter
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may influence the pancreatic b-cell function and insulin 
secretion via inhibition of glucose-induced Ca2+ signal-
ing pathways. Simvastatin, but not pravastatin, was also 
found to block the L-type Ca2+ channels, inhibiting insu-
lin secretion in rat islet b-cells [32]. Additionally, insulin 
release may also be impaired by decreased amount of 
adenosine triphosphate. Of note, statins suppress the 
ubiquinone biosynthesis, which results in delayed and 
reduced production of adenosine triphosphate [33]. 
Another postulated mechanism of statin diabetogenicity 
is the induction of b-cell apoptosis by nitric oxide [34]. 
As demonstrated in our meta-analysis and in other 
studies, statins do not exert a class effect on the new-on-
set DM occurrence and insulin sensitivity, however, 
substantial intra-class differences have been observed. 
According to a study by Baker et al., pravastatin sig-
nificantly improves insulin sensitivity as compared with 
placebo, while simvastatin worsens it [35]. Simvastatin 
was reported to significantly reduce concentration of 
adiponectin, a protein hormone attenuating glucone-
ogenesis and stimulating glucose uptake, and insulin 
sensitivity in hypercholesterolemic patients [36, 37]. 
It is hypothesized that lipophilic and hydrophilic statins 
have different effects on adiponectin and insulin re-
sistance. Pravastatin, a representative of hydrophilic 
statins, increases adiponectin concentration and in-
sulin sensitivity. In contrast, simvastatin was reported 
to significantly increase fasting insulin concentration, 
worsen insulin resistance and reduce adiponectin con-
centration [38]. Bhandari et al. postulated a possible link 
between statin therapy and downregulation of adipsin, 
a novel adipokine responsible for the stimulation of 
insulin secretion by pancreatic b-cells, resulting in an 
increased risk of new-onset DM [39]. Notably, glucose is 
transported into the cells via insulin-regulated transport-
ers. One of them, glucose transporter type 4 (GLUT-4) 
is responsible for glucose entrance to adipocytes and 
skeletal muscle cells. Atorvastatin was demonstrated to 
downregulate the expression of GLUT-4 in adipocytes, 
thus impairing glucose tolerance [40]. According to 
a hypothesis formulated by Chamberlain, statin-induced 
attenuation of GLUT-4 expression in adipocytes may be 
explained by inhibition of the isoprenoid synthesis [41]. 
Swerdlow et al. proved that glucose-rising effect of 
statins may be at least partially explained by HMG-CoA 
reductase inhibition [42]. They used single nucleotide 
polymorphisms (rs17238484-G and rs12916 alleles) in 
the enzyme HMG-CoA reductase gene as surrogates 
for HMG-CoA reductase inhibition by statins in a group 
of 223,463 patients. Having analyzed these genetic 
variants and a combination of their own and published 
data, the authors demonstrated that the presence of 
both investigated allelic variants was not only associ-
ated with a decreased HMG-CoA reductase activity, 
but also with a higher risk of statin-induced type 2 DM 
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(the rs17238484-G allele: OR 1.02; 95% CI 1.00–1.05; 
the rs12916 allele: OR 1.06; 95% CI 1.03–1.09).
Although the above proposed mechanisms could 
contribute to the diabetogenic effect of statins, a de-
finitive mechanism of this phenomenon has not been 
clarified so far.
Statin therapy in patients with 
diagnosed DM
It is important to emphasize that in patients with 
previously diagnosed DM statin therapy is a mainstay 
of treatment and brings substantial cardiovascular 
benefits. This was clearly established by the Cholesterol 
Treatment Trialists’ (CTT) Collaborators in a meta-anal-
ysis of fourteen randomized trials including 18,686 pa-
tients with DM (1466 with type 1 DM and 17220 with 
type 2 DM) and 71,370 non-diabetic patients [43]. Statin 
therapy, when compared with placebo/no treatment, led 
to a 9% decrease of all-cause mortality per 1 mmol/L 
reduction of LDL-cholesterol in participants with DM 
(RR 0.91; 99% CI 0.82–1.01), which was comparable to 
the 13% reduction in those without DM (RR 0.87; 99% 
CI 0.82–0.92). The mortality benefits in diabetics were 
mainly driven by reduced vascular mortality (RR 0.87; 
95% CI 0.76–1.00). There was also a 21% reduction 
in major vascular events per 1 mmol/L decrease of 
LDL-cholesterol concentration in DM patients (RR 0.79; 
99% CI 0.72–0.86), similarly to non-diabetics (RR 0.79; 
99% CI 0.76–0.82). Substantial reductions in myocardial 
infarction or coronary death (RR 0.78; 99% CI 0.69–0.87), 
coronary revascularization (RR 0.75; 99% CI 0.64–0.88), 
and stroke (RR 0.79; 99% CI 0.67–0.93) were observed 
in statin vs. placebo-treated diabetics. It should be ac-
knowledged that larger reductions in LDL-cholesterol 
concentration produced greater reductions in the oc-
currence of major vascular events. Notably, among DM 
individuals the observed cardiovascular benefits were 
largely irrespective of the initial lipid profile, previous 
vascular events or other baseline characteristics.
Tailored statin therapy 
with statins being used by hundreds of millions 
people all over the world, it is crucial to learn how to 
envisage their adverse metabolic effects in selected 
groups of patients. Physicians should be aware of the 
fact that there is a gradient for the risk of new-onset 
DM across different types and doses of statins [31]. 
Identifying the individuals who would benefit more from 
smaller doses or use of less diabetogenic compounds 
could help us to optimize the treatment and reduce the 
number of people developing DM during hypolipidemic 
therapy with statins. The moment when statin therapy 
should be employed in primary prevention also remains 
controversial and lacks clear definition. 
There are no doubts that the use of statins in patients 
with high cardiovascular risk is fully substantiated. Howev-
er, it is still uncertain where exactly lies the point beyond 
which statins’ beneficial and protective cardiovascular ac-
tions begin to outweigh their small, but apparent, diabeto-
genic risk. A recent meta-analysis by the aforementioned 
CTT Collaborators states that even patients with low risk 
of cardiovascular events gain benefit from cholesterol 
lowering treatment [44]. In their study, each 1 mmol/L 
reduction in LDL-cholesterol concentration produced 
an absolute reduction in major vascular events of about 
11 per 1000 over 5 years. Intriguingly, neither age, sex, 
baseline LDL-cholesterol, previous vascular disease, nor 
vascular and all-cause mortality had much impact on the 
volume of major vascular events risk reduction. Obviously, 
if patients at low risk of cardiovascular disease become 
diabetic, their risk of myocardial infarction, stroke, unsta-
ble angina or death from cardiovascular causes will sky-
rocket. The use of hypolipidemic medications with lower 
potential to negatively interfere with glucose metabolism 
would sound reasonable in such case. 
Based on our findings, pravastatin could be a good 
match for hyperlipidemic patients assessed to be at low 
cardiovascular risk. Despite its smaller potential to lower 
LDL-cholesterol concentration, at the same time it seems 
to be the least diabetogenic statin currently available on 
the market. Although a little bit forgotten and margin-
alized by newer, more powerful and more advertised 
statins, pravastatin could serve as a valuable alternative, 
especially for patients with preexisting predispositions 
for DM. Not to mention the economical aspect of a lower 
price which most likely could improve the consistency of 
treatment in all groups of patients. Alternative strategy for 
such patients could be more cautious dosage, regard-
less of the prescribed HMG-CoA reductase antagonist. 
As observed in our meta-analysis, the smaller the daily 
dose, the lower the incidence of DM.
In people with higher cardiovascular risk and/or very 
high values of LDL-cholesterol requiring more aggressive 
therapeutic approach, the treatment with more potent 
statins, but of worse metabolic profile, cannot be denied. 
The increased risk of developing DM indisputably has to 
be considered when introducing rosuvastatin or simvas-
tatin, but cannot be an excluding factor for such therapy. 
Nevertheless, physicians must be aware of the potential 
adverse metabolic effects deriving from the therapy 
consisting of specific statins or higher daily doses. On 
the other hand, the fact that statins are one of the most 
efficient known methods of cardiovascular prevention 
has to be kept in mind at all times. Moreover, it is crucial 
to remember, that statins cannot be accounted for all the 
new cases of DM diagnosed during the hypolipidemic 
therapy. A further analysis from the JUPITER trial clearly 
shows that the hazard of developing new-onset DM is 
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directly connected with the already preexisting DM risk 
factors [45]. That is why it is so important to put particular 
emphasis on non-pharmacological methods such as 
exercises, weight reduction and low fat diet. Additional 
motivation originating from the physician should not be 
neglected, as awareness of hypolipidemic therapy may 
diminish patients’ efforts to lead a healthier lifestyle, 
which in a short period of time can shift them to a higher 
cardiovascular risk group. These actions, even though 
very often insufficient, create a chance to decrease 
baseline LDL-cholesterol concentration and reduce the 
number of both cardiovascular and DM risk factors. 
It could enable us to employ a therapy with lower daily 
doses which, according to our meta-analysis, could con-
fine the number of statin-related DM cases, regardless 
of the chosen statin. This could be of great importance, 
particularly with more powerful compounds, but also 
when larger diabetogenic potential is used.
In our opinion, a regular control of a few commonly 
available lab tests such as fasting glucose, oral glu-
cose tolerance test or glycated hemoglobin as well 
as frequent reevaluation of DM risk factors should be 
recommended in patients chronically using statins. The 
closer monitoring could enable the early intervention 
and modification of therapy according to the patient’s 
most recent clinical status. Construction of a simple and 
clinically applicable scale stratifying patients accord-
ing to the statin-related DM risk, which would enable 
physicians to select a specific statin and dose for each 
patient, could improve the efficacy and safety of HMG-
CoA reductase antagonists treatment.
Effect of novel non-statin hypolipidemic 
drugs on new-onset DM
Routine lipid-lowering therapy is expected to be 
revolutionized in next years by the widespread use of 
novel non-statin hypolipidemic drugs, ezetimibe and, 
particularly, proprotein convertase subtilisin/kexin type 
9 inhibitors. Therefore, their impact on glucose metab-
olism is of major importance. 
Based on the results of a randomized, double-blind, 
placebo-controlled, parallel-group study investigating 
the effect of ezetimibe vs. placebo on glycated hemoglo-
bin (primary endpoint), glycoalbumin, and fasting plas-
ma glucose concentration in 152 patients with type 2 DM 
and hypercholesterolemia, Saito et al. found that 
ezetimibe, an inhibitor of a small intestine cholesterol 
transporter, does not impair glucose metabolism in this 
subset of patients [46]. Moreover, two smaller trials indi-
cated that ezetimibe can even improve glucose metab-
olism in DM patients [47, 48]. Additionally, a substudy 
of the IMPROVE-IT (IMProved Reduction of Outcomes: 
Vytorin Efficacy International Trial) trial presented during 
the recent European Society of Cardiology Congress 
in London indicated that: 1) diabetics receive greater 
benefit than nondiabetics with ezetimibe, and 2) ezeti-
mibe does not increase the risk of new-onset DM [49].
Interestingly, recent data from the ODYSSEY Phase 3 
program show no significant effect of alirocumab, a pro-
protein convertase subtilisin/kexin type 9 inhibitor, on 
glucose metabolism [50]. On the other hand, therapy 
with second novel proprotein convertase subtilisin/kex-
in type 9 inhibitor, evolocumab, was associated with 
a small increase in new-onset DM in patients with 
impaired fasting glucose [51]. 
Ongoing trials
Ongoing trials are expected to shed some light on 
the issues discussed in this review. However, much more 
research in this field is needed than the below summa-
rized studies registered in the ClinicalTrials.gov database.
The objective of the randomized, open label, place-
bo-controlled, parallel-group study Statins on Glucose 
Homeostasis in Subjects with Impaired Fasting Glucose 
is to evaluate the effects of rosuvastatin (probably the 
most diabetogenic statin) and pravastatin (probably 
protective in terms of the new-onset DM occurrence) 
on the glucose homeostasis and other biomarkers in 
160 subjects with impaired fasting glucose [52]. The 
study is currently recruiting participants.
The SIPHON (to Evaluate the Safety and Efficacy of 
Pitavastatin in Patients with Impaired Fasting Glucose 
and Hyperlipidemia) study is testing the hypothesis on 
the lack of difference between routine lipid-lowering ther-
apy (pitavastatin 2 mg q.s.) and intensive lipid-lowering 
therapy (pitavastatin 4 mg q.s.) on glycated hemoglobin 
concentration [53]. Of note, pitavastatin remains the 
most potent known statin which is also suggested not to 
deteriorate glucose metabolism. However, pitavastatin is 
not approved in Poland yet. The primary study outcome 
measure is the change of glycated hemoglobin concen-
tration before and after 24 weeks of treatment in a group 
of 318 patients with impaired fasting glucose and hyper-
lipidemia. The trial is also currently recruiting participants.
The PPCVD (Primary Prevention of Cardiovascular 
Disease in Pre-diabetic & Pre-hypertensive Subjects) 
aims to determine whether treating pre-diabetic and 
pre-hypertensive individuals using multiple drugs 
intervention (anti-hypertensive drugs [i.e., an angioten-
sin-converting-enzyme inhibitor] plus anti-glycemic drug 
[i.e., metformin] plus anti-hyperlipidemic drug [a statin]) 
would lower cardiovascular disease events [54]. 
The planned enrollment is 8900 patients. The study is 
not yet open for participants recruitment.
Another registered study not yet recruiting partici-
pants is the Statin Strategy Proposal Trial, whose ob-
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jective is to compare the intensity-based statin therapy 
with attained LDL-cholesterol-based statin protocol in 
patients with coronary artery disease [55]. The primary 
outcome measure is the occurrence of major adverse 
cardiac and cerebrovascular events within 3 years of 
follow-up in a group of estimated 4400 patients.
Conclusions
Statins are commonly used in everyday practice 
both in primary and secondary prevention of cardio-
vascular events. Statins’ status of superstar lipid-low-
ering drugs with exceptional cardiovascular benefits is 
undeniable and supported by overwhelming scientific 
evidence. with special caution regarding the patients 
with an increased risk of DM, and with the proposed 
personalized approach, statins should with ease defend 
their position of a cornerstone of cardiovascular pre-
vention. we cannot forget that statins are not the only 
diabetogenic drugs that are widely used in cardiology. 
Beta-blockers, thiazide diuretics and niacin also belong 
to this group. The adverse actions they exert on glucose 
metabolism did not exclude them from the routine use 
due to their favorable cardiovascular effects. 
In the guidelines for treating cardiac patients pub-
lished throughout the recent years the threshold of 
the optimal LDL-cholesterol concentration has been 
progressively lowered, following the rule “the lower, the 
better”. It entailed the use of more powerful statins and 
higher doses, which carries a numerically higher risk of 
new-onset DM. For that reason it would be advisable to 
be aware of the fact that in lower risk cases beginning 
the treatment with smaller daily doses, more careful 
dosage or choosing less diabetogenic compound could 
be more beneficial for the patient. There is no doubt that 
ungrounded use of higher doses of statins increases 
the probability of DM. This hazard is especially high in 
patients with already existing conditions like metabolic 
syndrome, obesity, impaired glucose tolerance or 
impaired fasting glucose In this subset of patients the 
use of novel non-statin hypolipidemic drugs can serve 
as a possible solution. Tailored therapy prepared indi-
vidually for each patient, after considering all the risk 
factors as well as potential benefits, may be an answer 
to our concerns. However, this concept should be 
further investigated v. the one-size-fits-all approach in 
future trials. Until such studies are completed, we ad-
vise to follow five simple rules listed in Figure 2, which 
may hopefully minimize the risk of new-onset DM in 
statin-treated patients.
In our opinion, profits derived from statin therapy 
far exceed the potential harms connected with sta-
tin-induced impairments of glucose metabolism. The 
association between statins and new-onset DM, al-
though appears to be petite, requires our consideration 
concerning the widespread use of these compounds 
and warrants further investigation of the mutual depen-
dencies between DM, statins and cardiovascular risk.
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